STOCK TITAN

[Form 4] Kineta, Inc. Common Stock Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Kineta Director Kimberlee C. Drapkin reported multiple securities transactions on Form 4, detailing changes in beneficial ownership on June 23-25, 2025:

  • Exercised 12,500 stock options at $0.611 per share on June 23
  • Disposed of 4,706 common shares at $0.26 per share through tax withholding (Form F)
  • Received 6,000 new shares as an award on June 25 at $0 cost

The transactions were executed following the approval of a merger agreement between Kineta and TuHURA Biosciences at a Special Meeting of Stockholders on June 23, 2025. Per the Optionholder Treatment Agreement dated June 16, 2025, and merger agreement dated December 11, 2024 (amended May 5, 2025), the reporting person's options under the 2022 Equity Incentive Plan became fully vested. Following all transactions, Drapkin directly owns 13,794 common shares with no remaining stock options.

La direttrice di Kineta, Kimberlee C. Drapkin, ha segnalato diverse operazioni su titoli nel Modulo 4, illustrando le variazioni nella proprietà effettiva tra il 23 e il 25 giugno 2025:

  • Ha esercitato 12.500 opzioni su azioni a $0,611 per azione il 23 giugno
  • Ha ceduto 4.706 azioni ordinarie a $0,26 per azione tramite ritenuta fiscale (Modulo F)
  • Ha ricevuto 6.000 nuove azioni come premio il 25 giugno a costo zero

Le operazioni sono state eseguite dopo l'approvazione di un accordo di fusione tra Kineta e TuHURA Biosciences durante l'Assemblea Speciale degli Azionisti del 23 giugno 2025. Secondo l'Accordo sul trattamento degli opzionisti datato 16 giugno 2025 e l'accordo di fusione del 11 dicembre 2024 (modificato il 5 maggio 2025), le opzioni della persona segnalante nell'ambito del Piano di Incentivi Azionari 2022 sono diventate completamente maturate. Dopo tutte le operazioni, Drapkin possiede direttamente 13.794 azioni ordinarie senza opzioni residue.

La directora de Kineta, Kimberlee C. Drapkin, informó varias transacciones de valores en el Formulario 4, detallando cambios en la propiedad beneficiaria entre el 23 y 25 de junio de 2025:

  • Ejerció 12,500 opciones sobre acciones a $0.611 por acción el 23 de junio
  • Dispuso de 4,706 acciones ordinarias a $0.26 por acción mediante retención fiscal (Formulario F)
  • Recibió 6,000 nuevas acciones como premio el 25 de junio a costo cero

Las transacciones se realizaron tras la aprobación de un acuerdo de fusión entre Kineta y TuHURA Biosciences en la Junta Especial de Accionistas del 23 de junio de 2025. Según el Acuerdo de Tratamiento de Titulares de Opciones fechado el 16 de junio de 2025 y el acuerdo de fusión del 11 de diciembre de 2024 (modificado el 5 de mayo de 2025), las opciones de la persona que reporta bajo el Plan de Incentivos de Capital 2022 se volvieron totalmente adquiridas. Tras todas las transacciones, Drapkin posee directamente 13,794 acciones ordinarias sin opciones restantes.

Kineta 이사 Kimberlee C. Drapkin은 2025년 6월 23일부터 25일까지의 실질 소유권 변동을 자세히 보고하는 Form 4에 여러 증권 거래를 신고했습니다:

  • 6월 23일 주당 $0.611에 12,500주 스톡옵션 행사
  • 세금 원천징수를 통해 주당 $0.26에 4,706주 보통주 처분(Form F)
  • 6월 25일 비용 없이 6,000주 신규 주식 수령(상금으로)

이 거래들은 2025년 6월 23일 주주 특별총회에서 Kineta와 TuHURA Biosciences 간 합병 계약이 승인된 후 실행되었습니다. 2025년 6월 16일자 옵션 보유자 처리 계약과 2024년 12월 11일(2025년 5월 5일 수정) 합병 계약에 따라, 보고자는 2022년 주식 인센티브 계획에 따른 옵션이 완전히 베스팅되었습니다. 모든 거래 후 Drapkin은 남은 스톡옵션 없이 13,794주의 보통주를 직접 보유하고 있습니다.

La directrice de Kineta, Kimberlee C. Drapkin, a déclaré plusieurs transactions sur titres via le formulaire 4, détaillant les changements de propriété bénéficiaire entre le 23 et le 25 juin 2025 :

  • Exercice de 12 500 options d'achat d'actions à 0,611 $ par action le 23 juin
  • Disposition de 4 706 actions ordinaires à 0,26 $ par action par retenue fiscale (formulaire F)
  • Réception de 6 000 nouvelles actions en tant que récompense le 25 juin à coût nul

Ces transactions ont été effectuées après l'approbation d'un accord de fusion entre Kineta et TuHURA Biosciences lors de l'assemblée générale extraordinaire des actionnaires le 23 juin 2025. Conformément à l'accord de traitement des détenteurs d'options daté du 16 juin 2025 et à l'accord de fusion du 11 décembre 2024 (modifié le 5 mai 2025), les options de la personne déclarant dans le cadre du plan d'incitation en actions 2022 sont devenues entièrement acquises. Après toutes les opérations, Drapkin détient directement 13 794 actions ordinaires sans options restantes.

Kineta-Direktorin Kimberlee C. Drapkin meldete mehrere Wertpapiertransaktionen im Formular 4 und detaillierte die Änderungen des wirtschaftlichen Eigentums vom 23. bis 25. Juni 2025:

  • Am 23. Juni wurden 12.500 Aktienoptionen zu je 0,611 $ ausgeübt
  • 4.706 Stammaktien wurden zu 0,26 $ pro Aktie durch Steuerabzug (Formular F) veräußert
  • Am 25. Juni erhielt sie 6.000 neue Aktien als Auszeichnung zum Nullkostenpreis

Die Transaktionen erfolgten nach der Genehmigung eines Fusionsvertrags zwischen Kineta und TuHURA Biosciences auf der außerordentlichen Hauptversammlung der Aktionäre am 23. Juni 2025. Gemäß der Optioninhaber-Behandlungsvereinbarung vom 16. Juni 2025 und dem Fusionsvertrag vom 11. Dezember 2024 (geändert am 5. Mai 2025) wurden die Optionen der meldenden Person gemäß dem Equity Incentive Plan 2022 vollständig unverfallbar. Nach allen Transaktionen besitzt Drapkin direkt 13.794 Stammaktien und hat keine verbleibenden Aktienoptionen.

Positive
  • Director received 6,000 shares as new stock grant, demonstrating continued alignment with shareholder interests
Negative
  • None.

La direttrice di Kineta, Kimberlee C. Drapkin, ha segnalato diverse operazioni su titoli nel Modulo 4, illustrando le variazioni nella proprietà effettiva tra il 23 e il 25 giugno 2025:

  • Ha esercitato 12.500 opzioni su azioni a $0,611 per azione il 23 giugno
  • Ha ceduto 4.706 azioni ordinarie a $0,26 per azione tramite ritenuta fiscale (Modulo F)
  • Ha ricevuto 6.000 nuove azioni come premio il 25 giugno a costo zero

Le operazioni sono state eseguite dopo l'approvazione di un accordo di fusione tra Kineta e TuHURA Biosciences durante l'Assemblea Speciale degli Azionisti del 23 giugno 2025. Secondo l'Accordo sul trattamento degli opzionisti datato 16 giugno 2025 e l'accordo di fusione del 11 dicembre 2024 (modificato il 5 maggio 2025), le opzioni della persona segnalante nell'ambito del Piano di Incentivi Azionari 2022 sono diventate completamente maturate. Dopo tutte le operazioni, Drapkin possiede direttamente 13.794 azioni ordinarie senza opzioni residue.

La directora de Kineta, Kimberlee C. Drapkin, informó varias transacciones de valores en el Formulario 4, detallando cambios en la propiedad beneficiaria entre el 23 y 25 de junio de 2025:

  • Ejerció 12,500 opciones sobre acciones a $0.611 por acción el 23 de junio
  • Dispuso de 4,706 acciones ordinarias a $0.26 por acción mediante retención fiscal (Formulario F)
  • Recibió 6,000 nuevas acciones como premio el 25 de junio a costo cero

Las transacciones se realizaron tras la aprobación de un acuerdo de fusión entre Kineta y TuHURA Biosciences en la Junta Especial de Accionistas del 23 de junio de 2025. Según el Acuerdo de Tratamiento de Titulares de Opciones fechado el 16 de junio de 2025 y el acuerdo de fusión del 11 de diciembre de 2024 (modificado el 5 de mayo de 2025), las opciones de la persona que reporta bajo el Plan de Incentivos de Capital 2022 se volvieron totalmente adquiridas. Tras todas las transacciones, Drapkin posee directamente 13,794 acciones ordinarias sin opciones restantes.

Kineta 이사 Kimberlee C. Drapkin은 2025년 6월 23일부터 25일까지의 실질 소유권 변동을 자세히 보고하는 Form 4에 여러 증권 거래를 신고했습니다:

  • 6월 23일 주당 $0.611에 12,500주 스톡옵션 행사
  • 세금 원천징수를 통해 주당 $0.26에 4,706주 보통주 처분(Form F)
  • 6월 25일 비용 없이 6,000주 신규 주식 수령(상금으로)

이 거래들은 2025년 6월 23일 주주 특별총회에서 Kineta와 TuHURA Biosciences 간 합병 계약이 승인된 후 실행되었습니다. 2025년 6월 16일자 옵션 보유자 처리 계약과 2024년 12월 11일(2025년 5월 5일 수정) 합병 계약에 따라, 보고자는 2022년 주식 인센티브 계획에 따른 옵션이 완전히 베스팅되었습니다. 모든 거래 후 Drapkin은 남은 스톡옵션 없이 13,794주의 보통주를 직접 보유하고 있습니다.

La directrice de Kineta, Kimberlee C. Drapkin, a déclaré plusieurs transactions sur titres via le formulaire 4, détaillant les changements de propriété bénéficiaire entre le 23 et le 25 juin 2025 :

  • Exercice de 12 500 options d'achat d'actions à 0,611 $ par action le 23 juin
  • Disposition de 4 706 actions ordinaires à 0,26 $ par action par retenue fiscale (formulaire F)
  • Réception de 6 000 nouvelles actions en tant que récompense le 25 juin à coût nul

Ces transactions ont été effectuées après l'approbation d'un accord de fusion entre Kineta et TuHURA Biosciences lors de l'assemblée générale extraordinaire des actionnaires le 23 juin 2025. Conformément à l'accord de traitement des détenteurs d'options daté du 16 juin 2025 et à l'accord de fusion du 11 décembre 2024 (modifié le 5 mai 2025), les options de la personne déclarant dans le cadre du plan d'incitation en actions 2022 sont devenues entièrement acquises. Après toutes les opérations, Drapkin détient directement 13 794 actions ordinaires sans options restantes.

Kineta-Direktorin Kimberlee C. Drapkin meldete mehrere Wertpapiertransaktionen im Formular 4 und detaillierte die Änderungen des wirtschaftlichen Eigentums vom 23. bis 25. Juni 2025:

  • Am 23. Juni wurden 12.500 Aktienoptionen zu je 0,611 $ ausgeübt
  • 4.706 Stammaktien wurden zu 0,26 $ pro Aktie durch Steuerabzug (Formular F) veräußert
  • Am 25. Juni erhielt sie 6.000 neue Aktien als Auszeichnung zum Nullkostenpreis

Die Transaktionen erfolgten nach der Genehmigung eines Fusionsvertrags zwischen Kineta und TuHURA Biosciences auf der außerordentlichen Hauptversammlung der Aktionäre am 23. Juni 2025. Gemäß der Optioninhaber-Behandlungsvereinbarung vom 16. Juni 2025 und dem Fusionsvertrag vom 11. Dezember 2024 (geändert am 5. Mai 2025) wurden die Optionen der meldenden Person gemäß dem Equity Incentive Plan 2022 vollständig unverfallbar. Nach allen Transaktionen besitzt Drapkin direkt 13.794 Stammaktien und hat keine verbleibenden Aktienoptionen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Drapkin Kimberlee C

(Last) (First) (Middle)
C/O KINETA, INC.
7683 SE 27TH STREET, SUITE 481

(Street)
MERCER ISLAND WA 98040

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
KINETA, INC./DE [ KANT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/23/2025 M 12,500 A $0.611 12,500 D
Common Stock 06/23/2025 F 4,706 D $0.26 7,794 D
Common Stock 06/25/2025 A 6,000 A $0 13,794 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $0.611 06/23/2025 M 12,500 (1) 09/03/2034 Common Stock 12,500 $0 0 D
Explanation of Responses:
1. Pursuant to the terms of (i) the Optionholder Treatment Agreement, dated June 16, 2025, by and between Kineta, Inc. (the "Company") and the Reporting Person, and (ii) the Agreement and Plan of Merger, dated as of December 11, 2024, by and among the Company, TuHURA Biosciences, Inc., a Nevada corporation ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of TuHURA, Hura Merger Sub II, a Delaware limited liability company and a wholly owned subsidiary of TuHURA, and Craig Philips, as representative of the stockholders of the Company, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025, as approved by the Company's stockholders at the Special Meeting of Stockholders held on June 23, 2025, the options granted to the Reporting Person under the 2022 Equity Incentive Plan became fully vested on June 23, 2025.
/s/ Nanette Agustines, as Attorney-in-Fact 06/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Kimberlee Drapkin make in KA stock on June 23, 2025?

On June 23, 2025, Kimberlee Drapkin exercised 12,500 stock options at $0.611 per share (acquired) and subsequently had 4,706 shares withheld for taxes (disposed) at $0.26 per share. After these transactions, she held 7,794 shares directly.

How many shares of KA stock did Kimberlee Drapkin receive as a grant on June 25, 2025?

Kimberlee Drapkin received a grant of 6,000 shares of KA common stock on June 25, 2025 at $0 cost, bringing her total direct holdings to 13,794 shares.

What was the exercise price of KA stock options that Drapkin exercised?

Kimberlee Drapkin exercised stock options with an exercise price of $0.611 per share. These options were originally set to expire on September 3, 2034, but were exercised early on June 23, 2025.

Why did KA director Kimberlee Drapkin's stock options vest early?

The options vested early on June 23, 2025, pursuant to an Optionholder Treatment Agreement dated June 16, 2025, and a merger agreement between Kineta and TuHURA Biosciences. This early vesting was approved by stockholders at a Special Meeting held on June 23, 2025.
Kineta, Inc.

NASDAQ:KA

KA Rankings

KA Latest News

KA Latest SEC Filings

KA Stock Data

7.05M
12.26M
34.89%
6%
0.23%
Biotechnology
Pharmaceutical Preparations
Link
United States
MERCER ISLAND